Literature DB >> 32372348

Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys.

S L Huskinson1, D M Platt2, M Brasfield2, M E Follett2, T E Prisinzano3, B E Blough4, K B Freeman2.   

Abstract

RATIONALE: Kappa-opioid receptor (KOR) agonists are antinociceptive but have side effects that limit their therapeutic utility. New KOR agonists have been developed that are fully efficacious at the KOR but may produce fewer or reduced side effects that are typical of KOR agonists.
OBJECTIVES: We determined behavioral profiles for typical and atypical KOR agonists purported to differ in intracellular-signaling profiles as well as a mu-opioid receptor (MOR) agonist, oxycodone, using a behavioral scoring system based on Novak et al. (Am J Primatol 28:124-138, 1992, Am J Primatol 46:213-227, 1998) and modified to quantify drug-induced effects (e.g., Duke et al. J Pharmacol Exp Ther 366:145-157, 2018).
METHODS: Six adult male rhesus monkeys were administered a range of doses of the typical KOR agonists, U50-488H (0.0032-0.1 mg/kg) and salvinorin A (0.00032-0.01 mg/kg); the atypical KOR agonists, nalfurafine (0.0001-0.001 mg/kg) and triazole 1.1 (0.01-0.32 mg/kg); the MOR agonist, oxycodone (0.0032-0.32 mg/kg); and as controls, cocaine (0.032-0.32 mg/kg) and ketamine (0.32-10 mg/kg). For time-course determinations, the largest dose of each KOR agonist or MOR agonist was administered across timepoints (10-320 min). In mixture conditions, oxycodone (0.1 mg/kg) was followed by KOR-agonist administration.
RESULTS: Typical KOR agonists produced sedative-like and motor-impairing effects. Nalfurafine was similar to typical KOR agonists on most outcomes, and triazole 1.1 produced no effects on its own except for reducing scratch during time-course determinations. In the mixture, all KOR agonists reduced oxycodone-induced scratching, U50-488H and nalfurafine reduced species-typical activity, and U50-488H increased rest/sleep posture.
CONCLUSIONS: Atypical "biased" KOR agonists produce side-effect profiles that are relatively benign (triazole 1.1) or reduced (nalfurafine) compared to typical KOR agonists.

Entities:  

Keywords:  Kappa-opioid receptor; Mu-opioid receptor; Observable behavior; Rhesus monkey

Mesh:

Substances:

Year:  2020        PMID: 32372348      PMCID: PMC7308209          DOI: 10.1007/s00213-020-05519-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  Selective antagonism of the ataxic effects of zolpidem and triazolam by the GABAA/alpha1-preferring antagonist beta-CCt in squirrel monkeys.

Authors:  Donna M Platt; James K Rowlett; Roger D Spealman; James Cook; Chunrong Ma
Journal:  Psychopharmacology (Berl)       Date:  2002-09-04       Impact factor: 4.530

2.  Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.

Authors:  Eduardo R Butelman; Marek Mandau; Kevin Tidgewell; Thomas E Prisinzano; Vadim Yuferov; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2006-10-23       Impact factor: 4.030

Review 3.  Kappa opioids and the modulation of pain.

Authors:  Bronwyn Kivell; Thomas E Prisinzano
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

Review 4.  Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.

Authors:  Ngoc Quan Phan; Tobias Lotts; Attila Antal; Jeffrey D Bernhard; Sonja Ständer
Journal:  Acta Derm Venereol       Date:  2012-09       Impact factor: 4.437

5.  Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures.

Authors:  Vanessa Minervini; Hannah Y Lu; Jahnavi Padarti; Daniela C Osteicoechea; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2018-05-22       Impact factor: 4.530

6.  Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.

Authors:  Matthew L Lazenka; Megan J Moerke; E Andrew Townsend; Kevin B Freeman; F Ivy Carroll; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2017-10-24       Impact factor: 4.530

7.  Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons.

Authors:  E M Weerts; N A Ator; D M Grech; R R Griffiths
Journal:  J Pharmacol Exp Ther       Date:  1998-04       Impact factor: 4.030

8.  Modulation of α5 subunit-containing GABAA receptors alters alcohol drinking by rhesus monkeys.

Authors:  Daniela Rüedi-Bettschen; James K Rowlett; Sundari Rallapalli; Terry Clayton; James M Cook; Donna M Platt
Journal:  Alcohol Clin Exp Res       Date:  2012-11-05       Impact factor: 3.455

Review 9.  Opioid receptors: drivers to addiction?

Authors:  Emmanuel Darcq; Brigitte Lina Kieffer
Journal:  Nat Rev Neurosci       Date:  2018-08       Impact factor: 34.870

Review 10.  Therapeutic Potential of Kappa Opioid Agonists.

Authors:  Tyler C Beck; Matthew A Hapstack; Kyle R Beck; Thomas A Dix
Journal:  Pharmaceuticals (Basel)       Date:  2019-06-20
View more
  12 in total

1.  Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.

Authors:  Mei-Chuan Ko; Stephen M Husbands
Journal:  Handb Exp Pharmacol       Date:  2020-12-04

2.  The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats.

Authors:  C Austin Zamarripa; Tanya Pareek; Hayley M Schrock; Thomas E Prisinzano; Bruce E Blough; Kenneth J Sufka; Kevin B Freeman
Journal:  Psychopharmacology (Berl)       Date:  2021-08-25       Impact factor: 4.530

3.  Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys.

Authors:  Lais F Berro; C Austin Zamarripa; Joseph T Talley; Kevin B Freeman; James K Rowlett
Journal:  Addict Behav       Date:  2022-07-22       Impact factor: 4.591

Review 4.  The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies.

Authors:  Martin L Dalefield; Brittany Scouller; Rabia Bibi; Bronwyn M Kivell
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

Review 5.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

Review 6.  An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.

Authors:  Alexander R French; Richard M van Rijn
Journal:  Pharmacol Res       Date:  2022-01-29       Impact factor: 7.658

7.  Tolerance and dependence following chronic alprazolam treatment in rhesus monkeys: Role of GABAA receptor subtypes.

Authors:  Angela N Duke; V V N Phani Babu Tiruveedhula; Dishary Sharmin; Daniel E Knutson; James M Cook; Donna M Platt; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2021-08-27       Impact factor: 4.492

8.  Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.

Authors:  Yan Zhou; Kevin Freeman; Vincent Setola; Danni Cao; Shane Kaski; Mary Jeanne Kreek; Lee-Yuan Liu-Chen
Journal:  Handb Exp Pharmacol       Date:  2022

Review 9.  Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.

Authors:  Shane W Kaski; Allison N White; Joshua D Gross; David P Siderovski
Journal:  Anesth Analg       Date:  2021-02-01       Impact factor: 6.627

Review 10.  Natural Products for the Treatment of Pain: Chemistry and Pharmacology of Salvinorin A, Mitragynine, and Collybolide.

Authors:  Soumen Chakraborty; Susruta Majumdar
Journal:  Biochemistry       Date:  2020-09-22       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.